Compensation for Gadolinium Toxicity from MRIs

The US Food and Drug Administration (FDA) announced it will require additional warnings for gadolinium-based contrast agents (GBCAs) alerting patients to a potential risk of gadolinium retention. The move comes after a hearing about gadolinium at which various experts and patients spoke about gadolinium retention in the human body, including in organs and the brain. Patients discussed the side effects of having gadolinium retained in their body.

Gadolinium-based contrast agents, or GBCAs, are injected in about a third of 60 million MRIs performed annually – 30 million in the U.S. alone (that’s one in 10 Americans), including children.

Gadolinium is a heavy metal chemical agent that is injected to enhance the images of a MRI. It not naturally found in the human body. Its proponents say it is always expelled from the body, primarily through the kidneys. But studies have shown it can be retained in the brain, bones, skin and others parts of the body.

Gadolinium Contrast Agents & Side Effects

Patients injected with a Gadolinium contrast agents may experience the following side effects:

  • Nephrogenic Systemic Fibrosis (NSF)
  • Shortness of breath
  • Hives
  • Facial swelling
  • Superficial inflammation
  • Irritation of blood vessels
  • Blood Clots
  • Headache
  • Nausea
  • Lightheadedness
  • Low blood pressure

FDA-approved Gadolinium-based contrast agents:

"There have been an increasing number of Adverse Events reported to the FDA since January 2016 regarding surgeons revising failed Aesculap Vega Knee Devices for aseptic loosening (non-infection related) where the surgeon notes the complete absence of cement bonded to either the femoral or tibial components."
  • Gadoterate (Dotarem by Guerbet LLC)
  • Gadodiamide (Omniscan by GE Healthcare)
  • Gadobenate (MultiHance by Bracco)
  • Gadopentetate (Magnevist by Bayer)
  • Gadoteridol (ProHance by Bracco)
  • Gadofosveset (Ablavar, formerly Vasovist, by Bayer)
  • Gadoversetamide (OptiMARK by Guerbet)
  • Gadoxetate (Eovist by Bayer)
  • Gadobutrol (Gadavist by Bayer)

Reports state the people who are at risk of developing NSF / NFD include patients with:

  • acute or chronic severe renal insufficiency (low kidney filtration rate)
  • kidney dysfunction due to hepatorenal syndrome (liver problems)
  • recent surgery, especially a liver transplant
  • any medical condition that affects the patient’s blood clotting ability.


Rate This Service

4.9/5 - (16 votes)

Did you or a loved one suffer side effects following an MRI as a result of Gadolinium Toxicity or poisoning?

Find out if you qualify for compensation.

Find Out More
Copyright © 2016-2017 Consumer Safety Watch. All Rights Reserved. Privacy / Terms / Disclaimer

Consumer Safety Watch offers safety advocate services and attorney referral services for patients throughout the United States including the states of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming.

Consumer Safety Watch offers consumer safety advocate services or can help you find an attorney throughout the United States including the following cities: Albuquerque, NM; Arlington, TX; Atlanta, GA; Austin, TX; Baltimore, MD; Boston, MA; Charlotte, NC; Chicago, IL; Cleveland, OH; Colorado Springs, CO; Columbus, OH; Dallas, TX; Denver, CO; Detroit, MI; Fresno, CA; Fort Worth, TX; Indianapolis, IN; Honolulu, HI; Houston, TX; Jacksonville, FL; Kansas City, KS; Kansas City, MO; Las Vegas, NV; Long Beach, CA; Los Angeles, CA; Louisville, KY; Memphis, TN; Mesa, AZ; Miami, FL; Miami, OH; Milwaukee, WI; Minneapolis, MN; Nashville, TN; New York City, NY; Oakland, CA; Oklahoma City, OK; Omaha, NE; Philadelphia, PA; Phoenix, AZ; Pittsburgh, PA; Portland, OR; Sacramento, CA; San Antonio, Tx; San Diego, CA; San Francisco, CA; San Jose, CA; Seattle, WA; St. Louis, MO; Tampa, FL; Tucson, AZ; Tulsa, Virginia Beach, VA; Washington, DC; Wichita, KS.